The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme disease in healthy adult participants.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
Timeframe: Up to Day 175 (7 days after each study injection)
Number of Participants With Unsolicited Adverse Events (AEs)
Timeframe: Up to Day 196 (28 days after each study injection)
Number of Participants With Medically Attended AEs
Timeframe: Day 1 through Day 337 (6 months after the last study injection)
Number of Participants with AEs of Special Interest, Serious AEs, and AEs Leading to Discontinuation of Study Injection or Study Participation
Timeframe: Day 1 through Day 505 (End of Study)